Who runs the clinical trials: academia, not pharma, 2026

ClinicalTrials.gov is the public ledger of medical research: every interventional and observational study a sponsor registers, with its phase, its conditions, its status — and the institution that runs it. Read for what is starting or stopping, the registry tells one story. Read for who is doing the registering and it tells another, one that cuts against the popular picture of clinical research as something pharmaceutical companies do. The sponsors on the registry are mostly not companies at all, and the few institutions that dominate the top of the list are mostly not pharma.

Academia runs the registry, not pharma

Of the 589,453 studies registered on ClinicalTrials.gov, 420,647 — 71.4% — are run by sponsors in the registry's "Other" class: universities, hospitals, and foundations. Industry runs 130,207, or 22.1%. Government sponsors of every kind combined run 5.4%.

Source: ClinicalTrials.gov, registered studies by lead-sponsor class, snapshot 2026-06-14. The remaining ~1,600 studies are filed by individual sponsors or carry no coded class.

The registry codes each study's lead sponsor into a class, and the "Other" bucket — academic medical centers, universities, hospital systems, and research foundations — is more than three times the size of industry. The three government classes (the NIH, other U.S. federal agencies, and other governments) together account for 31,990 studies, 5.4%. By the count of who registers studies, clinical research is an academic and hospital activity, and has been throughout the registry's history.

A sponsor count is a record of who registers research, not a measure of its quality, size, or importance. A university running many small studies and a company running a few large trials are different shapes of the same enterprise — the count describes the shape, nothing more.

The inversion: who runs the drug-development pipeline

Narrow the count to phased interventional trials — the regulated pipeline that tests a drug or biologic in humans — and the picture flips toward industry. Of the 220,186 phased trials, industry runs 41.2%, nearly double its 22.1% share of all studies; the academic share falls from 71.4% to 51.7%.

Source: ClinicalTrials.gov, phased interventional trials (Early Phase 1 through Phase 4) by lead-sponsor class, snapshot 2026-06-14.

This is the resolution of the apparent paradox. Academic sponsors run the most studies, but a large share of that volume is observational research and non-phased interventional work — behavioral, device, surgical, and procedural studies that never carry a drug-development phase label. Industry's footprint is the opposite shape: comparatively few studies overall, but heavily weighted toward the phased trials that move a candidate toward approval. Where the cost, the regulatory exposure, and the commercial stakes are highest, industry's share roughly doubles. "Pharma runs clinical trials" is true of the drug-development pipeline and false of the registry as a whole — and the two facts coexist in the same table.

Concentrated at the top, fragmented at the bottom

The registry is steeply concentrated among its most prolific sponsors. The top 100 sponsors — 0.2% of the 50,756 distinct lead sponsors — run 26.2% of all registered studies. The top 1,000 run 62.7%.

Source: ClinicalTrials.gov, share of registered studies run by the N most prolific lead sponsors, snapshot 2026-06-14.

That concentration sits on top of an enormous thin tail. 53.8% of all lead sponsors registered exactly one study, and 82.4% registered five or fewer — the median sponsor appears on the registry once and never again.

Source: ClinicalTrials.gov, distribution of lead sponsors by number of registered studies, snapshot 2026-06-14.

These are two faces of one distribution. A short head of standing research institutions — academic medical centers, large hospital systems, and the bigger pharmaceutical companies — registers studies year after year and accumulates thousands each. Behind them stretches a tail of more than 27,000 sponsors that registered a single study: a one-off investigator-initiated trial, a small clinic's pilot, a one-time collaboration. The registry is not a list of equals; it is a power law.

The most prolific sponsors are universities

Among the 100 most prolific lead sponsors, 79 are academic or hospital institutions, and they account for 73.3% of all studies run by the top 100. Only 16 of the top 100 are industry sponsors.

Source: ClinicalTrials.gov, lead-sponsor class of the 100 most prolific sponsors, snapshot 2026-06-14.

The concentration at the head of the registry is academic, not industrial. The handful of industry sponsors that crack the top 100 are large and familiar pharmaceutical companies, but they are outnumbered nearly five to one by universities, national cancer centers, and hospital systems that each run thousands of studies. The institutions that register the most clinical research are the same kind of institutions that run the bulk of it — and they are overwhelmingly academic. Industry's weight shows up not at the very top of the sponsor list but in the type of trial it concentrates on, as the phased-pipeline table shows.

What one row actually is

Each row in clinical_trials is one registered study: its NCT identifier, brief and official titles, overall status, study type and phase, lead sponsor and sponsor class, enrollment count, conditions, start and completion dates, and the listed overall officials. The published registry is the current roster of registered studies as of the snapshot, and counting and grouping these rows by sponsor and sponsor class is the entire method here. A sponsor is identified by lead_sponsor_name; sponsor "class" is the registry's own lead_sponsor_class coding. Investigator and official names are present where ClinicalTrials.gov published them, but the name-to-entity-graph link is deferred and held, so no trial, sponsor, or investigator renders on any individual provider profile. Every figure in this study is a count or percentage at the sponsor-class or sponsor-cohort level. No investigator, sponsor, or trial is named, ranked, or scored.

Methodology

All figures are direct aggregations over the clinical_trials table, populated from the ClinicalTrials.gov Data API v2 — the U.S. National Library of Medicine's registry of interventional and observational clinical studies. The table holds 589,453 registered studies across 50,756 distinct lead sponsors; snapshot 2026-06-14; public, read-only; license per the ClinicalTrials.gov Terms & Conditions for NLM public data. Fonteum re-pulls the registry on snapshot publication, so figures advance with each refresh.

Sponsor-class shares are computed over the whole registry — every registered study, regardless of status — because the question is who registers research, not how it ends. The "academic / hospital" group is the registry's OTHER class; "industry" is INDUSTRY; "government" combines NIH, FED (other U.S. federal), and OTHER_GOV. The phased-pipeline cut restricts to interventional trials whose phase is one of the seven phased buckets (Early Phase 1 through Phase 4), the set of trials that test a drug or biologic in humans. Concentration figures rank lead sponsors by their number of registered studies and sum the top N; the one-study and five-or-fewer figures count sponsors by their study total. Because these are counts and ratios over a published registry, every figure is exact as of the snapshot rather than estimated. Methodology version: clinicaltrials/v1. The source-provenance contract is documented in the provenance methodology.

Limitations

• A record of registration, not of quality or importance. A sponsor count measures how many studies an institution has registered. It is unrelated to the quality, size, cost, or scientific importance of that research, and unrelated to exclusion, sanction, or any assessment of an investigator's or provider's conduct. This study draws no inference about any party from a sponsor count.
• Aggregate and category-level only. Every figure is a count or percentage at the sponsor-class or sponsor-cohort level. No investigator, sponsor, or individual trial is named, ranked, or scored, and the name-to-entity-graph link is deferred, so no trial renders on any provider profile.
• The registry is global, not U.S.-only. ClinicalTrials.gov is the U.S. NLM registry mandated for federally funded and FDA-regulated research, but it lists studies sponsored worldwide. "Who runs the trials" here is a count over all registered sponsors, including non-U.S. institutions, not a United States–only tally.
• Sponsor class is the registry's own coding. The academic / industry / government split follows the lead_sponsor_class field as ClinicalTrials.gov records it. A small number of studies carry no coded class or an individual sponsor; these are reported as their own rows and excluded from the three named groups.
• Lead sponsor only; collaborators are not counted. Each study is attributed to its single lead sponsor. Industry-funded studies run under an academic lead sponsor, and collaborations, are counted under the lead sponsor — so industry's true financial footprint is wider than its lead-sponsor share.
• Snapshot, not a trend model. Figures reflect the single registry snapshot dated 2026-06-14. The registry is refreshed on publication and grows continuously, so shares shift between releases; this study does not model change over time.

Sources

• ClinicalTrials.gov — the U.S. National Library of Medicine registry behind every figure in this study.
• ClinicalTrials.gov Data API v2 — the public API Fonteum pulls the registry snapshot from.
• ClinicalTrials.gov — sponsor and collaborator definitions — the official definitions of lead sponsor and the sponsor classes used to group studies here.

The companion dataset page for ClinicalTrials.gov Studies lists the full schema and refresh cadence, and the clinical-trials data explorer exposes the underlying records. For the other half of the registry's story — where these trials stop — see the Phase 2 valley where clinical trials discontinue; for the drug-and-device lifecycle the industry pipeline feeds, the 2026 drug and device recall landscape; and for who funds the clinical economy these sponsors sit inside, the manufacturers behind industry payments to clinicians, the pharma payments tied to GLP-1 prescribing, the changing shape of Medicare enrollment, and who opts out of Medicare entirely.